BidaskClub upgraded shares of Intra-Cellular Therapies (NASDAQ:ITCI) from a strong sell rating to a sell rating in a research note published on Tuesday, February 13th.
Other equities analysts also recently issued reports about the company. Zacks Investment Research raised Intra-Cellular Therapies from a hold rating to a buy rating and set a $16.00 target price for the company in a research note on Wednesday, January 3rd. Royal Bank of Canada assumed coverage on Intra-Cellular Therapies in a research note on Thursday, February 8th. They set an outperform rating and a $33.00 target price for the company. SunTrust Banks raised Intra-Cellular Therapies from a hold rating to a buy rating in a research note on Wednesday, November 8th. Canaccord Genuity assumed coverage on Intra-Cellular Therapies in a report on Friday, December 15th. They issued a buy rating and a $31.00 price target on the stock. Finally, ValuEngine cut Intra-Cellular Therapies from a sell rating to a strong sell rating in a report on Sunday, December 31st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $26.70.
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) opened at $19.97 on Tuesday. Intra-Cellular Therapies has a one year low of $7.85 and a one year high of $22.67.
In other Intra-Cellular Therapies news, Chairman Sharon Mates sold 11,257 shares of the stock in a transaction on Friday, January 5th. The stock was sold at an average price of $17.08, for a total transaction of $192,269.56. Following the sale, the chairman now owns 1,099,964 shares in the company, valued at approximately $18,787,385.12. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Michael Halstead sold 25,500 shares of the stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $18.03, for a total value of $459,765.00. Following the sale, the senior vice president now owns 191 shares in the company, valued at approximately $3,443.73. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,160 shares of company stock worth $966,934. Insiders own 21.00% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. MetLife Investment Advisors LLC acquired a new stake in Intra-Cellular Therapies during the 4th quarter valued at $246,000. Millennium Management LLC boosted its holdings in shares of Intra-Cellular Therapies by 18.0% during the fourth quarter. Millennium Management LLC now owns 1,454,944 shares of the biopharmaceutical company’s stock worth $21,068,000 after purchasing an additional 221,980 shares during the last quarter. TIAA CREF Investment Management LLC boosted its holdings in shares of Intra-Cellular Therapies by 61.5% during the fourth quarter. TIAA CREF Investment Management LLC now owns 174,620 shares of the biopharmaceutical company’s stock worth $2,528,000 after purchasing an additional 66,464 shares during the last quarter. Teachers Advisors LLC boosted its holdings in shares of Intra-Cellular Therapies by 25.5% during the fourth quarter. Teachers Advisors LLC now owns 78,406 shares of the biopharmaceutical company’s stock worth $1,135,000 after purchasing an additional 15,912 shares during the last quarter. Finally, Raymond James & Associates acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth $237,000. Hedge funds and other institutional investors own 76.93% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “BidaskClub Upgrades Intra-Cellular Therapies (NASDAQ:ITCI) to “Sell”” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/20/intra-cellular-therapies-itci-upgraded-to-sell-by-bidaskclub.html.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.